Prostate cancer: data support adding ADT for patients undergoing post-operative radiotherapy
Results from the RADICALS-HD and PRESTO trials show encouraging metastasis-free and biochemical progression-free survival benefits with androgen deprivation therapy, but they are not practice-changing yet
First-line triplet of TKI plus dual immunotherapy improves outcomes in renal cell carcinoma
Results from the COSMIC-313 trial show that adding cabozantinib to nivolumab plus ipilimumab prolongs progression-free survival, but also increases toxicity
Antibody–drug conjugates show potential in advanced solid tumours
Study data report promising responses and safety profiles in patients with heavily pre-treated malignancies
NECs: mixed results for second-line therapy after progression
The optimal chemotherapy regimen in this setting is not well-defined
The first randomised study of peptide receptor radionuclide therapy in pancreatic NETs met its primary endpoint
In the OCLURANDOM trial, progression-free survival was longer in patients receiving lutetium-octreotate versus sunitinib
Can new routes of administration have a place in the application of immunotherapy?
Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients
Nivolumab shows encouraging efficacy in high-risk patients with precancerous oral lesions
Results of a small phase II trial may open up a new option for some patients with leukoplakia, but toxicity of immunotherapy is high and questions remain about its utility in clinical practice
Intensive follow-up and ctDNA screening may improve detection of early recurrence in CRC patients
Patients with resected stage II–III CRC may benefit from earlier detection of recurrence, enabling more to receive surgery with curative intent, but further work is needed to determine the most reliable and cost-effective methods of follow-up
Potential new treatment options for metastatic colorectal cancer emerge from two studies
Encouraging clinical activity was reported for fruquintinib and the combination therapy of trastuzumab plus tucatinib in heavily pre-treated patients with manageable safety profiles
New data show promise of targeted treatment combinations in advanced KRAS G12C-mutated colorectal cancer
Although further evidence is needed, targeting mutant KRAS with novel agents and combinations may offer new options for patients with advanced colorectal cancer